Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Tillman

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Genetics|October 6, 2018
Endoplasmic Reticulum Homeostasis Is Modulated by the Forkhead Transcription Factor FKH-9 During Infection of <i>Caenorhabditis elegans</i>Erik J Tillman, Claire E Richardson, Douglas J Cattie, et al.
Clinical Chemistry|February 1, 1989
How sensitive are immunometric assays for thyrotropin?M G McConway, R S Chapman, G H Beastall, et al.
Oncogene|February 26, 2013
Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5E L Mora-Blanco, Y Mishina, E J Tillman, et al.
Cell Cycle (Georgetown, Tex.)|May 1, 2012
Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumorsElizabeth S McKenna, Pablo Tamayo, Yoon-Jae Cho, et al.
Pancreas|September 14, 2017
Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms After Total PancreatectomyMaarten R Struyvenberg, Zhi Ven Fong, Camilia R Martin, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 4, 2023
Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxiferminAdam S Kinne, Erik J Tillman, Sanofar J Abdeen, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2006
Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmiasStephan E Lehnart, Cecile Terrenoire, Steven Reiken, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2023
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosisStephen A Harrison, Peter J Ruane, Bradley Freilich, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2013
Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promotersMichael Y Tolstorukov, Courtney G Sansam, Ping Lu, et al.
Nature Medicine|July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trialStephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Genetics|October 6, 2018
Endoplasmic Reticulum Homeostasis Is Modulated by the Forkhead Transcription Factor FKH-9 During Infection of <i>Caenorhabditis elegans</i>Erik J Tillman, Claire E Richardson, Douglas J Cattie, et al.
Clinical Chemistry|February 1, 1989
How sensitive are immunometric assays for thyrotropin?M G McConway, R S Chapman, G H Beastall, et al.
Oncogene|February 26, 2013
Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5E L Mora-Blanco, Y Mishina, E J Tillman, et al.
Cell Cycle (Georgetown, Tex.)|May 1, 2012
Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumorsElizabeth S McKenna, Pablo Tamayo, Yoon-Jae Cho, et al.
Pancreas|September 14, 2017
Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms After Total PancreatectomyMaarten R Struyvenberg, Zhi Ven Fong, Camilia R Martin, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 4, 2023
Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxiferminAdam S Kinne, Erik J Tillman, Sanofar J Abdeen, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 5, 2006
Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmiasStephan E Lehnart, Cecile Terrenoire, Steven Reiken, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2023
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosisStephen A Harrison, Peter J Ruane, Bradley Freilich, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2013
Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promotersMichael Y Tolstorukov, Courtney G Sansam, Ping Lu, et al.
Nature Medicine|July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trialStephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
Pageof 8